Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Surg. Jun 27, 2026; 18(6): 116682
Published online Jun 27, 2026. doi: 10.4240/wjgs.116682
Published online Jun 27, 2026. doi: 10.4240/wjgs.116682
Expression of LHFPL2 in hepatocellular carcinoma and its association with prognosis after transarterial chemoembolization
Lei Sun, Kang Chen, Department of Interventional Radiology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi 214023, Jiangsu Province, China
Xiao-Li Zhu, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Suzhou 215031, Jiangsu Province, China
Author contributions: Sun L and Chen K contributed to methodology, formal analysis, investigation, data curation, writing original draft; Zhu XL contributed to resources, supervision, funding acquisition, and writing, reviewing, and editing; and all authors thoroughly reviewed and endorsed the final manuscript.
Institutional review board statement: This study was approved by the Medical Ethics Committee of Affiliated Wuxi People’s Hospital of Nanjing Medical University, approval No. KY25229.
Informed consent statement: All study participants and their legal guardians provided written informed consent before enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Corresponding author: Xiao-Li Zhu, MD, Chief Physician, Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, No. 188 Shizi Road, Suzhou 215031, Jiangsu Province, China. zhuxiaoli90@163.com
Received: January 6, 2026
Revised: February 7, 2026
Accepted: April 1, 2026
Published online: June 27, 2026
Processing time: 159 Days and 11 Hours
Revised: February 7, 2026
Accepted: April 1, 2026
Published online: June 27, 2026
Processing time: 159 Days and 11 Hours
Core Tip
Core Tip: Lipoma HMGIC fusion partner-like 2 overexpression contributes to transarterial chemoembolization resistance in hepatocellular carcinoma patients and predicts unfavorable outcomes. The combination of lipoma HMGIC fusion partner-like and alpha-fetoprotein levels allows for improved prognostic assessment, offering a potential molecular marker for individualized treatment planning and early identification of transarterial chemoembolization non-responders (No. AF-SW-07-02.1).